Pfenex

Headquartered in San Diego, California, PfÄ“nex Inc. is a leading biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars. The Company's core technology, PfÄ“nex Expression Technologyâ„¢, is a cutting edge protein expression platform that utilizes the BSL-1 microorganism Pseudomonas fluorescens. PfÄ“nex Expression Technologyâ„¢ combines an extensive toolbox of expression components with a robotically enabled high throughput parallel strain screening technology, delivering unprecedented speed and success in identifying protein production strains expressing high titers of soluble active protein.

Ligand Pharmaceuticals

SAN DIEGO, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain specified milestone is achieved, expired at midnight (New York

Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

PFENEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pfenex Inc. - PFNX

SAN DIEGO, Aug. 12, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Pfenex Inc.

(PFNX) Alert: Johnson Fistel Investigates Proposed Sale of Pfenex; Are Shareholders Getting a Fair Deal?

NEW YORK, Aug. 12, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Pfenex Inc.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Pfenex Inc. - PFNX

NEW YORK, Aug. 11, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.

New York, New York--(Newsfile Corp. - August 11, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Pfenex Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Pfenex Inc. to Ligand Pharmaceuticals Incorporated

Investors need to pay close attention to Pfenex (PFNX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Pfenex (PFNX) Stock?

Pfenex Inc. (PFNX) CEO Eef Schimmelpennink on Q2 2020 Results - Earnings Call Transcript

Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Pfenex (PFNX) Q2 Earnings Expected to Decline

SAN DIEGO, July  20, 2020  (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020. Pfenex will host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Pfenex to Announce Second Quarter Financial Results on August 6

SAN DIEGO, June  26, 2020  (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today the achievement of several significant milestones across their business portfolio. Theramex, the European commercialization partner for Pfenex and Adalvo (formerly Alvogen B2B), received a positive opinion for PF708 (branded in Europe as Livogiva™) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).  Additionally, Adalvo recently entered into a commercialization agreement with a multinational pharmaceutical company to commercialize PF708, upon receipt of marketing authorization, in certain countries in Latin America.

Pfenex Announces Positive European CHMP Opinion for PF708 (EU Brand Name: Livogiva™) and New Partnership in Latin America, and Provides CRM197 Business Update

SAN DIEGO, June  12, 2020  (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States.  Teriparatide Injection (also referred to as PF708 and Bonsity™) is a prescription medicine approved for several uses, including in postmenopausal women with osteoporosis who are at high risk for having bone fractures.

Pfenex Announces U.S. Commercial Launch of Teriparatide Injection

Pfenex's (PFNX) CEO Eef Schimmelpennink on Q1 2020 Results - Earnings Call Transcript

Analysts Estimate Pfenex (PFNX) to Report a Decline in Earnings: What to Look Out for

FDA review for a Therapeutic Equivalency rating for PF708 continues FDA review for a Therapeutic Equivalency rating for PF708 continues

Pfenex Announces FDA Requests Additional Comparative Use Human Factors Data in Experienced Users in order to Complete PF708 Therapeutic Equivalence Determination

Pfenex Inc. (PFNX) CEO Eef Schimmelpennink on Q4 2019 Results - Earnings Call Transcript

Pfenex (PFNX) delivered earnings and revenue surprises of 20.83% and 14.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Pfenex (PFNX) Q4 Earnings and Revenues Beat Estimates

SAN DIEGO, Jan.  08, 2020  (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization (WHO) prequalification for Pneumosil, a 10-valent pneumococcal conjugate vaccine. Pneumosil contains the recombinant carrier protein CRM197 produced by Serum Institute under a license to the Pfenex Expression Technology®.  

Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL®, containing CRM197 produced in Pfenex Expression Technology

Pfenex: Update; Still A Buy For Their Therapeutic Proteins Platform

SAN DIEGO, Dec.  18, 2019  (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated with process development activities for PF745, a long-acting Erwinia asparaginase.

Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals

SAN DIEGO, Nov.  13, 2019  (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial Officer effective November 13, 2019, but will continue to support the company by providing transition services until February 1, 2020. The company is conducting a search for a successor.

Pfenex Announces Management Change

Pfenex, Inc. (PFNX) CEO Eef Schimmelpennink on Q3 2019 Results - Earnings Call Transcript

Pfenex (PFNX) delivered earnings and revenue surprises of 0.00% and 3.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Pfenex (PFNX) Matches Q3 Earnings Estimates

Pfenex (PFNX) Reports Next Week: Wall Street Expects Earnings Growth

Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks

News for Pfenex Stock (PFNX)